These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11939559)

  • 1. Applications of affinity chromatography to the study of drug-melanin binding interactions.
    Aubry AF
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Feb; 768(1):67-74. PubMed ID: 11939559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug accumulation in melanin: an affinity chromatographic study.
    Knörle R; Schniz E; Feuerstein TJ
    J Chromatogr B Biomed Sci Appl; 1998 Sep; 714(2):171-9. PubMed ID: 9766857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a melanin-based high-performance liquid chromatography stationary phase and its use in the study of drug-melanin binding interactions.
    Ibrahim H; Aubry AF
    Anal Biochem; 1995 Aug; 229(2):272-7. PubMed ID: 7485982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Throughput Melanin-Binding Affinity and In Silico Methods to Aid in the Prediction of Drug Exposure in Ocular Tissue.
    Reilly J; Williams SL; Forster CJ; Kansara V; End P; Serrano-Wu MH
    J Pharm Sci; 2015 Dec; 104(12):3997-4001. PubMed ID: 26524700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Phototoxicity Testing Strategy for Accurate Photosafety Evaluation of Pharmaceuticals Based on the Assessment of Possible Melanin-Binding Effects.
    Reinen J; van Sas P; van Huygevoort T; Rubio L; Scase K; Wenker M
    Int J Toxicol; 2018; 37(4):296-307. PubMed ID: 29898631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of drugs to eye melanin is not predictive of ocular toxicity.
    Leblanc B; Jezequel S; Davies T; Hanton G; Taradach C
    Regul Toxicol Pharmacol; 1998 Oct; 28(2):124-32. PubMed ID: 9927562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanin binding study of clinical drugs with cassette dosing and rapid equilibrium dialysis inserts.
    Pelkonen L; Tengvall-Unadike U; Ruponen M; Kidron H; Del Amo EM; Reinisalo M; Urtti A
    Eur J Pharm Sci; 2017 Nov; 109():162-168. PubMed ID: 28756205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of drug binding to melanin using a melanin-based high-performance liquid chromatographic stationary phase and chemometric analysis of the chromatographic data.
    Kaliszan R; Kaliszan A; Wainer IW
    J Chromatogr; 1993 Jun; 615(2):281-8. PubMed ID: 8335705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic beads method for determination of binding of drugs to melanin.
    Marszałł MP; Buciński A; Goryński K; Proszowska A; Kaliszan R
    J Chromatogr A; 2011 Jan; 1218(2):229-36. PubMed ID: 21144529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Affinity of drugs for dopa-auto-oxidation melanin and tyrosinase-catalyzed dopa-melanin in vitro.
    Hayasaka S; Tsuchiya M; Noda S; Setogawa T; Mizuno K
    Ophthalmic Res; 1988; 20(6):376-9. PubMed ID: 3148876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development and characterization of protein-based stationary phases for studying drug-protein and protein-protein interactions.
    Sanghvi M; Moaddel R; Wainer IW
    J Chromatogr A; 2011 Dec; 1218(49):8791-8. PubMed ID: 21704318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calculation of drug-melanin binding energy using molecular modeling.
    Raghavan PR; Zane PA; Tripp SL
    Experientia; 1990 Jan; 46(1):77-80. PubMed ID: 2298284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo models to evaluate the role of ocular melanin in trans-scleral drug delivery.
    Pescina S; Santi P; Ferrari G; Padula C; Cavallini P; Govoni P; Nicoli S
    Eur J Pharm Sci; 2012 Aug; 46(5):475-83. PubMed ID: 22484210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinal pigment epithelium melanin and ocular toxicity.
    Dayhaw-Barker P
    Int J Toxicol; 2002; 21(6):451-4. PubMed ID: 12537641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Performance Affinity Chromatography: Applications in Drug-Protein Binding Studies and Personalized Medicine.
    Li Z; Beeram SR; Bi C; Suresh D; Zheng X; Hage DS
    Adv Protein Chem Struct Biol; 2016; 102():1-39. PubMed ID: 26827600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of drug-melanin interactions to ocular pharmacology and toxicology.
    Salazar-Bookaman MM; Wainer I; Patil PN
    J Ocul Pharmacol; 1994; 10(1):217-39. PubMed ID: 8207328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanin affinity and its possible role in neurodegeneration.
    Karlsson O; Lindquist NG
    J Neural Transm (Vienna); 2013 Dec; 120(12):1623-30. PubMed ID: 23821370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Affinity of ocular acid-insoluble melanin for drugs in vitro.
    Tsuchiya M; Hayasaka S; Mizuno K
    Invest Ophthalmol Vis Sci; 1987 May; 28(5):822-5. PubMed ID: 3570692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Affinity chromatography: a review of clinical applications.
    Hage DS
    Clin Chem; 1999 May; 45(5):593-615. PubMed ID: 10222345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of drug interactions with serum proteins by using high-performance affinity chromatography.
    Hage DS; Anguizola J; Barnaby O; Jackson A; Yoo MJ; Papastavros E; Pfaunmiller E; Sobansky M; Tong Z
    Curr Drug Metab; 2011 May; 12(4):313-28. PubMed ID: 21395530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.